BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

Go back to BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
(NASDAQ: BBIO) Delayed: 67.74 +0.19 (0.28%)
Previous Close $67.55    52 Week High $ 
Open $68.04    52 Week Low $ 
Day High $68.79    P/E N/A 
Day Low $67.55    EPS $ 
Volume 3,036,099